

May 04, 2016

Boehringer Ingelheim (Canada) Ltd. receives approval for Metacam® 20* for the alleviation of pain and inflammation in sheep

FOR IMMEDIATE RELEASE

Boehringer Ingelheim (Canada) Ltd. receives approval for Metacam® 20* for the alleviation of pain and inflammation in sheep

Burlington, Ontario (May 2, 2016) – Boehringer Ingelheim's Metacam® 20 has obtained approval in Canada for use in the alleviation of pain and inflammation in sheep. This is the first approval for Metacam® 20 in sheep worldwide.

The marketing authorization was granted based on Colditz et al. Efficacy of Meloxicam in Sheep: Determining the effective dose of meloxicam in a sterile model of inflammation in sheep (2011, unpublished).

In sheep, Metacam® 20 (meloxicam) is given as a single subcutaneous injection of 1.0mL/20kg bodyweight.

The approval comes following a joint submission from Boehringer Ingelheim in Canada, Australia and New Zealand that saw regulatory agencies from each country participate in a collaborative review process. The regulatory agencies for each country maintained the right to determine whether a product was approved for its own market. The joint submission and simultaneous review mark an important achievement in international regulatory cooperation.

Metacam® is non-steroidal anti-inflammatory drug of the oxicam class. Following the joint submission and review process, it is now licensed for use in sheep in three countries.

Metacam® 20 for use in sheep is a new indication for Boehringer Ingelheim's cattle product and demonstrates the company's commitment to animal welfare across a range of species.

About Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health is committed to fostering the health and well-being of mankind by promoting the emotional and physical benefits arising from the human animal bond. It has been providing solutions for the prevention and treatment of diseases in animals for almost 60 years

About Boehringer Ingelheim (Canada) Ltd.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of more than 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of its net sales.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

For more information please visit www.boehringer-ingelheim.ca